Eli Lilly and Co's blockbuster new drug "Tirzepatide" has filed its fifth marketing application in China.

On December 14, the latest announcement on the CDE website states that Eli Lilly and Co (LLY.US) has had its new indication application for the blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection accepted.

Zhitong FinanceDec 15 16:19

Broadcom rises over 8% again, with a cumulative increase of over 35% in two days! Which company will become the next member of the "trillion Market Cap club"?

After Broadcom's market cap exceeded one trillion dollars, there are currently nine companies in the "trillion-dollar market cap club" in the U.S. stock market, namely Apple, Microsoft, NVIDIA, Amazon, Google, Meta, Tesla, Broadcom, and Taiwan Semiconductor.

Futu News11minutes ago

INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) have reached a commercialization agreement for "Jepalin" in mainland China.

INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a collaboration agreement regarding the rights of Eli Lilly’s non-covalent (reversible) BTK inhibitor "Jehpaili" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sale, promotion, and distribution of Jehpaili, while Eli Lilly will be responsible for the research and development and post-marketing medical affairs related work for Jehpaili. INNOVENT BIO's founder, Chairman and CEO Yu Dechao expressed great pleasure in further deepening the strategic cooperation with Eli Lilly, noting that Jehpaili is the latest generation, the first and only globally approved non-covalent (reversible) BTK inhibitor.

AASTOCKS10:04

INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.

On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.

Zhitong Finance09:24

Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca

Breakings07:56

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China

PR Newswire07:55